Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. / Vedtofte, Louise; Knop, Filip K.; Vilsboll, Tina.

I: Expert Review of Clinical Pharmacology, Bind 8, Nr. 3, 01.05.2015, s. 273-282.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Vedtofte, L, Knop, FK & Vilsboll, T 2015, 'Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide', Expert Review of Clinical Pharmacology, bind 8, nr. 3, s. 273-282. https://doi.org/10.1586/17512433.2015.1029455

APA

Vedtofte, L., Knop, F. K., & Vilsboll, T. (2015). Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. Expert Review of Clinical Pharmacology, 8(3), 273-282. https://doi.org/10.1586/17512433.2015.1029455

Vancouver

Vedtofte L, Knop FK, Vilsboll T. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. Expert Review of Clinical Pharmacology. 2015 maj 1;8(3):273-282. https://doi.org/10.1586/17512433.2015.1029455

Author

Vedtofte, Louise ; Knop, Filip K. ; Vilsboll, Tina. / Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. I: Expert Review of Clinical Pharmacology. 2015 ; Bind 8, Nr. 3. s. 273-282.

Bibtex

@article{1ca6daf7b87c4ac497b7be1c9822df42,
title = "Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide",
abstract = "Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.",
keywords = "Basal insulin, DUAL I, DUAL II, fixed combination, GLP-1RA, IDegLira, incretin mimetic, insulin degludec, liraglutide, Type 2 diabetes",
author = "Louise Vedtofte and Knop, {Filip K.} and Tina Vilsboll",
note = "Publisher Copyright: {\textcopyright} Informa UK, Ltd.",
year = "2015",
month = may,
day = "1",
doi = "10.1586/17512433.2015.1029455",
language = "English",
volume = "8",
pages = "273--282",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide

AU - Vedtofte, Louise

AU - Knop, Filip K.

AU - Vilsboll, Tina

N1 - Publisher Copyright: © Informa UK, Ltd.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.

AB - Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.

KW - Basal insulin

KW - DUAL I

KW - DUAL II

KW - fixed combination

KW - GLP-1RA

KW - IDegLira

KW - incretin mimetic

KW - insulin degludec

KW - liraglutide

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84928618601&partnerID=8YFLogxK

U2 - 10.1586/17512433.2015.1029455

DO - 10.1586/17512433.2015.1029455

M3 - Review

C2 - 25816888

AN - SCOPUS:84928618601

VL - 8

SP - 273

EP - 282

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -

ID: 305734696